SG11201804263PA - Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor - Google Patents
Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitorInfo
- Publication number
- SG11201804263PA SG11201804263PA SG11201804263PA SG11201804263PA SG11201804263PA SG 11201804263P A SG11201804263P A SG 11201804263PA SG 11201804263P A SG11201804263P A SG 11201804263PA SG 11201804263P A SG11201804263P A SG 11201804263PA SG 11201804263P A SG11201804263P A SG 11201804263PA
- Authority
- SG
- Singapore
- Prior art keywords
- bothell
- drive
- international
- washington
- fucose
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 4
- SQTFKIKSQNCWGJ-KCDKBNATSA-N (2s,3r,4r,5s)-2-fluoro-3,4,5-trihydroxyhexanal Chemical compound C[C@H](O)[C@@H](O)[C@@H](O)[C@H](F)C=O SQTFKIKSQNCWGJ-KCDKBNATSA-N 0.000 title abstract 3
- 201000011510 cancer Diseases 0.000 title abstract 3
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 title abstract 2
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 title abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 239000007943 implant Substances 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property -' Organization International Bureau ristspi id (43) International Publication Date .... .....r ,„„0 8 June 2017 (08.06.2017) W I P0 1 PCT ID Hit (10) 11111111 WO Ill International 1111111111 IIIII II 2017/096274 III IIIIIIIIIIIIIII Publication IIIIIIIIIIIIII Al Number RIO IIII IIIIIIII (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 31/7024 (2006.01) A61K 39/395 (2006.01) kind of national protection available): AE, AG, AL, AM, A61K 31/7042 (2006.01) C07K 16/28 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, A61K 31/70 (2006.01) C07K 16/32 (2006.01) BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, A61K 31/02 (2006.01) DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, (21) International Application Number: KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, PCT/US2016/064783 MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, (22) International Filing Date: OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, 2 December 2016 (02.12.2016) SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, (25) Filing Language: English ZW. (26) Publication Language: English (84) Designated States (unless otherwise indicated, for every (30) Priority Data: kind of regional protection available): ARIPO (BW, GH, 62/263,228 4 December 2015 (04.12.2015) US GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, 62/308,583 15 March 2016 (15.03.2016) US TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, 62/321,857 13 April 2016 (13.04.2016) US TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, (71) Applicant: SEATTLE GENETICS, INC. [US/US]; LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, 21823 30th Drive SE, Bothell, Washington 98021 (US). SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, (72) Inventors: GARDAI, Shyra; 21823 30th Drive SE, GW, KM, ML, MR, NE, SN, TD, TG). Bothell, Washington 98021 (US). LAW, Che-Leung; Declarations under Rule 4.17: 21823 30th Drive SE, Bothell, Washington 98021 (US). be — as to applicant's entitlement to apply for and granted a SENTER, Peter; 21823 30th Drive SE, Bothell, Washing- patent (Rule 4.170) ton 98021 (US). OKELEY, Nicole; 21823 30th Drive SE, Bothell, Washington 98021 (US). FIELD, Jessica; 21823 — as to the applicant's entitlement to claim the priority of the 30th Drive SE, Bothell, Washington 98021 (US). earlier application (Rule 4.17(iii)) (74) Agents: LIN, Min al.; Seattle Genetics, Inc., 21823 30th Published: et Drive SE, Bothell, Washington 98021 (US). — with international search report (Art 21(3)) Title: CANCER TREATMENT USING 2-DEOXY-2-FLUORO-L-FUCOSE IN COMBINATION WITH A CHECKPOINT (54) INHIBITOR Figure 11 100 AP- Untreated -M-2FF To 80- -A- Anti-PD1 91 60- m -0- 2FF + Anti-PD1 Cl) . 6' 1-1 a) 40 - .4t 2 a) il• 0 - 20- 11\" - - el 0. . . . C) 0 01 0 IN 1-1 O (57) : The present invention is an effective amount of 2-deoxy-2-fluoro-L-fucose 0 with a checkpoint inhibitor. 20 40 60 80 100 Days post tumor implant directed to methods for treating cancer comprising administering to a subject in need thereof or a prodrug thereof, or a pharmaceutically acceptable salt thereof, in combination
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562263228P | 2015-12-04 | 2015-12-04 | |
| US201662308583P | 2016-03-15 | 2016-03-15 | |
| US201662321857P | 2016-04-13 | 2016-04-13 | |
| PCT/US2016/064783 WO2017096274A1 (en) | 2015-12-04 | 2016-12-02 | Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201804263PA true SG11201804263PA (en) | 2018-06-28 |
Family
ID=58797961
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10202005298RA SG10202005298RA (en) | 2015-12-04 | 2016-12-02 | Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor |
| SG11201804263PA SG11201804263PA (en) | 2015-12-04 | 2016-12-02 | Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10202005298RA SG10202005298RA (en) | 2015-12-04 | 2016-12-02 | Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20180353524A1 (en) |
| EP (1) | EP3383404A4 (en) |
| JP (1) | JP6906520B2 (en) |
| KR (1) | KR20180086233A (en) |
| CN (1) | CN108289903B (en) |
| AU (1) | AU2016362993A1 (en) |
| BR (1) | BR112018011261A2 (en) |
| CA (1) | CA3005997A1 (en) |
| EA (1) | EA201891340A1 (en) |
| IL (1) | IL259479B (en) |
| MX (1) | MX385283B (en) |
| SG (2) | SG10202005298RA (en) |
| WO (1) | WO2017096274A1 (en) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TR201902439T4 (en) | 2010-08-05 | 2019-03-21 | Seattle Genetics Inc | Methods of inhibition of protein fucosylation in vivo using fucose analogs. |
| JP7066696B2 (en) | 2016-10-11 | 2022-05-13 | アジェナス インコーポレイテッド | Anti-LAG-3 antibody and its usage |
| UA128783C2 (en) | 2017-06-07 | 2024-10-23 | Сіджен Інк. | T-CELLS WITH REDUCED SURFACE FUCOSYRATION AND THEIR METHODS OF OBTAINING AND USING |
| WO2019075449A1 (en) * | 2017-10-13 | 2019-04-18 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Fucosylation and immune surveillance in melanoma |
| TW202023625A (en) | 2018-08-23 | 2020-07-01 | 美商西雅圖遺傳學公司 | Anti-tigit antibodies |
| JP2022514299A (en) * | 2018-12-19 | 2022-02-10 | シージェン インコーポレイテッド | Controlled fucosylation of antibodies |
| US20220305038A1 (en) * | 2019-08-16 | 2022-09-29 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Fucosylation and immune modulation in cancer |
| CN111973749B (en) * | 2020-09-07 | 2023-03-21 | 威海人生药业集团股份有限公司 | Pharmaceutical composition for anti-tumor immunotherapy |
| IL305883A (en) | 2021-03-18 | 2023-11-01 | Seagen Inc | Selective drug release from internalized conjugates of biologically active compounds |
| WO2022221766A1 (en) * | 2021-04-16 | 2022-10-20 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Fucosylation and immune modulation in cancer |
| CN113274502B (en) * | 2021-05-05 | 2023-01-03 | 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） | Compositions for specific type three-negative breast cancer immunotherapy |
| US20240238318A1 (en) * | 2021-05-06 | 2024-07-18 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | L-fucose and anti-androgen receptor therapy for treatment of cancer |
| CN113413465B (en) * | 2021-06-15 | 2022-06-03 | 北京大学 | Application of fucosylation inhibitor in resisting inflammation caused by cancer |
| CN115466297B (en) * | 2022-08-25 | 2023-07-07 | 青岛农业大学 | Application of L-fucose and animal feed |
| WO2024077106A2 (en) * | 2022-10-04 | 2024-04-11 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Leveraging l-fucose-mediated signaling to induce monocyte-derived dendritic cell polarization |
| WO2024191807A1 (en) | 2023-03-10 | 2024-09-19 | Seagen Inc. | Methods of treating cancer with anti-tigit antibodies |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TR201902439T4 (en) | 2010-08-05 | 2019-03-21 | Seattle Genetics Inc | Methods of inhibition of protein fucosylation in vivo using fucose analogs. |
| EA201690912A1 (en) | 2013-11-05 | 2016-10-31 | Когнейт Биосервисис, Инк. | COMBINATION INHIBITORS OF CONTROL POINTS AND THERAPEUTIC REMEDIES FOR THE TREATMENT OF CANCER |
-
2016
- 2016-12-02 WO PCT/US2016/064783 patent/WO2017096274A1/en not_active Ceased
- 2016-12-02 SG SG10202005298RA patent/SG10202005298RA/en unknown
- 2016-12-02 CN CN201680071076.0A patent/CN108289903B/en not_active Expired - Fee Related
- 2016-12-02 CA CA3005997A patent/CA3005997A1/en not_active Abandoned
- 2016-12-02 AU AU2016362993A patent/AU2016362993A1/en not_active Abandoned
- 2016-12-02 EA EA201891340A patent/EA201891340A1/en unknown
- 2016-12-02 KR KR1020187017824A patent/KR20180086233A/en not_active Withdrawn
- 2016-12-02 MX MX2018006674A patent/MX385283B/en unknown
- 2016-12-02 SG SG11201804263PA patent/SG11201804263PA/en unknown
- 2016-12-02 US US15/781,256 patent/US20180353524A1/en not_active Abandoned
- 2016-12-02 BR BR112018011261A patent/BR112018011261A2/en not_active Application Discontinuation
- 2016-12-02 JP JP2018528650A patent/JP6906520B2/en active Active
- 2016-12-02 EP EP16871645.4A patent/EP3383404A4/en not_active Withdrawn
-
2018
- 2018-05-21 IL IL259479A patent/IL259479B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN108289903B (en) | 2021-08-03 |
| CN108289903A (en) | 2018-07-17 |
| IL259479A (en) | 2018-07-31 |
| MX2018006674A (en) | 2018-11-09 |
| AU2016362993A1 (en) | 2018-07-12 |
| CA3005997A1 (en) | 2017-06-08 |
| MX385283B (en) | 2025-03-18 |
| KR20180086233A (en) | 2018-07-30 |
| JP6906520B2 (en) | 2021-07-21 |
| JP2019501145A (en) | 2019-01-17 |
| EP3383404A4 (en) | 2019-07-31 |
| EA201891340A1 (en) | 2018-11-30 |
| EP3383404A1 (en) | 2018-10-10 |
| IL259479B (en) | 2022-03-01 |
| WO2017096274A1 (en) | 2017-06-08 |
| SG10202005298RA (en) | 2020-07-29 |
| US20180353524A1 (en) | 2018-12-13 |
| BR112018011261A2 (en) | 2018-11-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201804263PA (en) | Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor | |
| SG11201804373VA (en) | Compositions and methods for immunooncology | |
| SG11201808222RA (en) | Methods of treatment of cholestatic diseases | |
| SG11201906431UA (en) | Method for the treatment of thromboembolism | |
| SG11201811470PA (en) | Pyrazolopyrimidine derivatives as kinase inhibitor | |
| SG11201811564QA (en) | Methods of treating ovarian cancer | |
| SG11201808125RA (en) | Methods for solid tumor treatment | |
| SG11201901063SA (en) | Therapeutic agents for neurodegenerative diseases | |
| SG11201803920TA (en) | Compounds and compositions useful for treating disorders related to ntrk | |
| SG11201808676RA (en) | Methods of treating pediatric cancers | |
| SG11201804704PA (en) | Compositions and methods for decreasing tau expression | |
| SG11201804268RA (en) | Conjugates of quaternized tubulysin compounds | |
| SG11201901534VA (en) | Combination therapy with controlled-release cnp agonists | |
| SG11201807977XA (en) | Cancer therapy with an oncolytic virus combined with a checkpoint inhibitor | |
| SG11201900132QA (en) | Selecting neoepitopes as disease-specific targets for therapy with enhanced efficacy | |
| SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
| SG11201408240TA (en) | Treatment of motor and movement disorder side effects associated with parkinson's disease treatments | |
| SG11201805755SA (en) | Methods of administering hepcidin | |
| SG11201810940XA (en) | Methods of treating pancreatic cancer | |
| SG11201901389XA (en) | Combination therapy with glutaminase inhibitors | |
| SG11201803643TA (en) | Virulence attenuated bacteria for treatment of malignant solid tumors | |
| SG11201807526SA (en) | Combination therapy using a liv1-adc and a chemotherapeutic | |
| SG11201803915UA (en) | Echinomycin formulation, method of making and method of use thereof | |
| SG11201804597TA (en) | Vaccination with mica/b alpha 3 domain for the treatment of cancer | |
| SG11201809882XA (en) | Pharmaceutical combinations for treating cancer |